Linear Source Registry for Prostate Cancer

This registry is being conducted to provide long term analysis on the use of the linear
Civastring source for prostate cancer. Prospective data collection will record and
demonstrate biochemical response rates. Long term side effects and adverse events will be
monitored.

Inclusion Criteria:

- Age > 18 years old

- Plans to remain in care of enrolling physician for 5 years

- > 5 years life expectancy

- Signed informed consent

- Enrolled within 6 weeks of implant or within 365 days of prior implant

Exclusion Criteria:

- Not willing or able to comply with protocol visit schedule